Stephen Bloch Sells 3,596 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 3,596 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $79.55, for a total value of $286,061.80. Following the sale, the director owned 776,477 shares in the company, valued at $61,768,745.35. The trade was a 0.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Liquidia Stock Performance

Shares of NASDAQ LQDA opened at $86.82 on Thursday. Liquidia Corporation has a 12-month low of $16.82 and a 12-month high of $91.10. The company has a market cap of $7.72 billion, a price-to-earnings ratio of 620.19 and a beta of 0.55. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The stock’s 50 day simple moving average is $72.81 and its 200 day simple moving average is $51.36.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia’s revenue was up 4187.1% on a year-over-year basis. Equities research analysts expect that Liquidia Corporation will post 3.02 EPS for the current year.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia will report its second-quarter 2026 financial results on August 12, 2026. The update should provide investors with insight into YUTREPIA sales, operating performance and the company’s outlook. Liquidia Second Quarter 2026 Results Announcement
• Positive Sentiment: LifeSci Capital maintained a Buy rating, while Buckley Capital Advisors cited potential upside of more than 50% based on a prospective YUTREPIA ruling and possible buyout interest. These views support the bullish case, although they depend on regulatory and strategic outcomes. LifeSci Capital Buy Rating Buckley Capital Liquidia Investor Letter
• Neutral Sentiment: Recent coverage highlights a valuation debate: YUTREPIA could drive substantial growth, but patent risks and the stock’s elevated valuation may limit further gains. Shares trade at roughly 620 times earnings, making execution especially important.
• Negative Sentiment: Several insiders reported sales. Director Stephen Bloch sold 178,596 shares for about $15.2 million across July 20–23, while Jason Adair and Chief Accounting Officer Dana Boyle sold smaller amounts on July 27. The latter transactions were conducted under Rule 10b5-1 plans to cover tax withholding, reducing their negative significance; nevertheless, the director’s larger sales may encourage profit-taking concerns. Liquidia Insider Sales SEC Filing

Analyst Ratings Changes

A number of research firms recently weighed in on LQDA. Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a report on Monday, May 11th. Wall Street Zen lowered shares of Liquidia from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 27th. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Bank of America reaffirmed a “neutral” rating and set a $79.00 price target (up from $64.00) on shares of Liquidia in a report on Monday, June 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Liquidia currently has a consensus rating of “Moderate Buy” and an average target price of $86.18.

Institutional Investors Weigh In On Liquidia

Several institutional investors have recently bought and sold shares of LQDA. Northwestern Mutual Wealth Management Co. acquired a new position in Liquidia during the 4th quarter valued at about $25,000. Covestor Ltd raised its position in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after buying an additional 359 shares in the last quarter. NewEdge Advisors LLC acquired a new stake in shares of Liquidia in the 2nd quarter worth approximately $25,000. Fluent Financial LLC acquired a new stake in shares of Liquidia in the 2nd quarter worth approximately $287,000. Finally, Fulcrum Equity Management bought a new position in shares of Liquidia in the second quarter valued at approximately $399,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).